ACADEMIC AND RESEARCH PEER-REVIEWED MEDICAL JOURNALISSN 1727-2378 (Print)         ISSN 2713-2994 (Online)
Ru
En

Successful Use of Tocilizumab in a Child with Systemic Juvenile Idiopathic Arthritis

DOI:10.31550/1727-2378-2021-20-3-70-72
For citation: Aksenov A.V., Ivanovskaya E.A. Successful Use of Tocilizumab in a Child with Systemic Juvenile Idiopathic Arthritis. Doctor.Ru. 2021; 20(3): 70–72. (in Russian). DOI: 10.31550/1727-2378-2021-70-72
19 April 00:00
A.V. Aksenov E.A. Ivanovskaya

Objective of the Paper: To demonstrate a case of successful use of tocilizumab in a child with systemic juvenile idiopathic arthritis (JIA).

Key Points. A clinical variant of JIA is systemic arthritis (systemic JIA). Currently, management of systemic JIA includes tocilizumab, a recombinant humanised anti–interleukin-6 receptor monoclonal antibody. The article describes a case of successful use of tocilizumab in a child with systemic JIA after inefficient therapy with glucocorticosteroids and methotrexate.

Conclusion. Systemic JIA is the severest clinical JIA variant. Tocilizumab allows achieving the quiescent disease stage where the standard therapy with glucocorticosteroids and methotrexate is ineffective.

Contributions: Aksenov, A.V. — thematic publications reviewing, manuscript preparation; Ivanovskaya, E.A. — patient management in Rheumatology Unit.

Conflict of interest: The authors declare that they do not have any conflict of interests.

A.V. Aksenov (Corresponding author) — South Ural State Medical University of the Ministry of Health of the Russian Federation; 64 Vorovskiy Str., Chelyabinsk, Russian Federation 454092. E-mail: alexandr.axyonov@yandex.ru

E.A. Ivanovskaya — Children's City Clinical Hospital No.8; 2 Druzhby Str., Chelyabinsk, Russian Federation 454047. E-mail: Ivanovskava.Elena@yandex.ru

Доктор.ру

Received: 02.02.2021

Accepted: 19.03.2021

19 April 00:00
LITERATURE
  1. Alekseeva E.I., Valieva S.I., Bzarova T.M. et al. Treating systemic juvenile idiopathic arthritis with tocilizumab: clinical case. Pediatric Pharmacology. 2016; 13(4): 390–4. (in Russian). DOI: 10.5690/pf.v13i4.1613
  2. Alekseeva E.I., Litvitskiy P.F., Baranov A.A. eds. Juvenile rheumatoid arthritis: aetiology, pathogenesis, clinical findings, algorithms of diagnosis and management. Manual for medical professional, teachers, and scientists. M.: Vedi; 2007. 368 p (in Russian)
  3. Seraya V.A., Zholobova E.S., Vitebskaya A.V. et al. Dynamics of growth of children with systemic form of juvenile rheumatoid arthritis during therapy with tocilizumab and other biological agents. Clinical Practice in Pediatrics. 2016; 11(2): 15–22. (in Russian). DOI: 10.20953/1817-7646-2016-2-15-22
  4. Alexeeva E., Dvoryakovskaya T., Isaeva K. et al. AB0930 Efficacy of tocilizumab in treatment of systemic juvenile idiopathic arthritis in patients with macrophage activation syndrome. Ann. Rheumatic Dis. 2019; 78(suppl.2): S1931. DOI: 10.1136/annrheumdis-2019-eular.6680
  5. Horneff G., Schulz A.C., Klotsche J. et al. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile rheumatoid arthritis patients from the BIKER registry. Arthritis Res. Ther. 2017; 19(1): 256. DOI: 10.1186/s13075-017-1462-2
  6. Kikuchi J., Kondo T., Shibata A. et al. Efficacy and tolerability of six-week extended dosing interval with tocilizumab therapy in a prospective cohort as remission maintenance in patients with rheumatoid arthritis. Mod. Rheumatol. 2018; 28(3): 444–51. DOI: 10.1080/14397595.2017.1366092
  7. Pardeo M., De Benedetti F., Wang J. et al. Neutropenia during tocilizumab treatment is not associated with infection risk in systemic or polyarticular-course juvenile idiopathic arthritis. J. Rheumatol. 2019; 46(6): 1117–26. DOI: 10.3899/jtheum. 180795
  8. Turnier J.L., Brunner H.I. Tocilizumab for treating juvenile idiopathic arthritis. Exp. Opin. Biol. Ther. 2016; 16(4): 559–66. DOI: 10.1517/14712598.2016.1150997
  9. Shingarova M.Sh., Alekseeva E.I., Bzarova T.M. et al. The effect of tocilizumab on the condition of bone tissue of patients with systematic juvenile idiopatic arthritis: results of a series of cases retrospective study. Pediatric Pharmacology. 2016; 13(6): 560–4. (in Russian). DOI: 10.15690/pf.v13i6.1669

News

30 June 00:00
A New Issue of Doctor.Ru Neurology Psychiatry, Vol. 20, No. 5 (2021), Published

Find original articles and reviews covering various aspects of neurology, psychiatry and the interview with Professor Marina Arkadievna Kinkulkina

28 June 00:00
A New Issue of Doctor.Ru Internal Medicine, Vol. 20, No. 4 (2021), Published

Find original articles and reviews covering various aspects of cardiology, gastroenterology, internal medicine and the interview with Professor Elena Zelikovna Golukhova

 

3 May 17:06
A New Issue of Doctor.Ru Pediatrics, Vol. 20, No. 3 (2021), Published

Find original articles and reviews covering various aspects of pediatrics and the interview with Professor Evgeny Grigorievich Furman

3 May 17:06
A New Issue of Doctor.Ru Endocrinology, Vol. 20, No. 2 (2021), Published

Find original articles and reviews covering various aspects of endocrinology and the interview with Professor Valentin Viktorovich Fadeev

16 April 11:57
Igor Evgenievich Khatkov joined the American Surgical Association

Igor Evgenievich Khatkov, Head of A. S. Loginov Moscow Clinical Scientific and Practical Centre, Chief Oncologist in and for Moscow is now an honoured member of the American Surgical Association.

All news